Progressive Pulmonary Fibrosis Clinical Landscape Report 2026: Trials, Readouts and White Space

Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.

Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.

Executive view

Progressive Pulmonary Fibrosis remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 85 matched trial records and 36 indexed result records before the decision-focused sample below was selected.

How PatSnap MCP built this report

The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.

Trial landscape table

The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.

What indexed results say

• DUAL TARGETING OF JOINT AND LUNG DISEASE: EFFICACY OF TOFACITINIB PLUS IGURATIMOD COMBINATION IN PROGRESSIVE FIBROSING RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (Not Applicable): the indexed record reports CRp = 20.2 mg/dL; CRp = 5.1 mg/dL.
• Safety and Tolerability of Nintedanib in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Final Results of 2-Year Post-Marketing Surveillance (Not Applicable): the indexed record reports ADR = 60.29 %.
• A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) (Phase 3): the indexed record reports Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52(Least Squares Mean) = -165.77 Milliliters (mL) (95% Confidence Interval, -190.52 to -141.03); Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52(Least Squares Mean) = -98.59 Milliliters (mL) (95% Confidence Interval, -123.74 to -73.44); Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52(Least Squares Mean): Mean Difference (Net) = 81.14(95% CI, 45.95 - 116.32), P-Value = <0.0001; Mean Difference (Net) = 67.18(95% CI, 31.91 - 102.46), P-Value = 0.0002.

Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.

Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.

Asset and sponsor context

PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including The selected trials include interventions that are not yet normalized to an asset record. Company & Deal Intelligence records identify sponsor context for Peking Union Medical College Hospital, The University of California, San Francisco, China-Japan Friendship Hospital, General Hospital of Ningxia Medical University. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.

Where the white space is

1. Clinically meaningful endpoints paired with virologic or microbiologic measures.
2. Evidence in immunocompromised, pediatric, pregnant and older populations.
3. Resistance surveillance and combination strategies for prolonged infection.
4. Coadministration, real-world effectiveness and implementation studies.

Strategic implications

For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.

What to monitor next

Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.

Bottom line

Progressive Pulmonary Fibrosis has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.